Bevacizumab + IFN

Regimen

• Bevacizumab (Avastin) 10 mg/kg iv q2w until disease progression
• IFN α-2a 9 million IU sc tiw for 1 yr

References

Escudier B et al. A randomized, controlled, double-blinded phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon a2a as first-line therapy in metastatic renal cell carcinoma. 2007 ASCO annual meeting. Abstract 3